EHC/eu-patient.eu
Oct 16, 2026, 12:30
Why VWF Therapies Belong on the EU Critical Medicines List – EHC
EHC – European Haemophilia Consortium shared a post on LinkedIn:
“For many people with von Willebrand Disease (VWD), von Willebrand Factor (VWF) replacement is the only effective treatment. If supply runs short, there is no fallback.
That’s why the EHC is asking the European Medicines Agency and EU Member States to add VWF therapies to the EU List of Critical Medicines, so their supply gets closer monitoring and stronger safeguards. 🇪🇺
Swipe through for the key questions, and read the full campaign.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH
-
Oct 16, 2026, 10:07Habib Bennaceur: Building a Stronger Care Pathway for Sickle Cell Disease in India
-
Oct 16, 2026, 09:59Tareq Abadl: A Simple Guide to Blood Collection Tubes